Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Archimedes to develop novel intranasal granisetron product

Archimedes to develop novel intranasal granisetron product

16th June 2009

Archimedes will be responsible for developing the formulation of a novel intranasal granisetron product under a new agreement.

It has teamed up with Almac to work on the medication, which is hoped will provide rapid, well-tolerated and convenient therapy for patients suffering from chemotherapy-induced nausea and vomiting. It uses Archimedes’ ChiSys delivery technology.

Galen, a company that looks after Almac’s sales and marketing, will receive a number of royalties and milestone payments throughout the progression and launch of the item as part of the deal.

Vice-president of Archimedes’ research and development division Dr Alan Smith explained pre-clinical data from the firm’s intranasal granisetron product has so far been promising.

“[The compound] holds wide commercial potential by delivering an effective, easily administered and fast-acting treatment for patients who are already severely ill,” he stated.

Dr Iain James, vice-president of Almac’s Biology department, added the company is looking forward to working with Archimedes on the project.

Last month, the latter firm announced its clinical results from a phase III study showed NasalFent could be an effective therapy to help alleviate breakthrough cancer pain.

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.